Anticoagulation Monitoring in Surgical Patients

Fundamental Principles

The American Heart Association recommends using aPTT to monitor unfractionated heparin therapy, while PT (expressed as INR) is used to monitor warfarin therapy, with the choice depending on the anticoagulant the surgical patient is receiving 1
aPTT measures the intrinsic and common coagulation pathways, specifically monitoring the effect of unfractionated heparin and direct thrombin inhibitors on factors XII, XI, IX, VIII, X, V, II, and fibrinogen 1

The therapeutic aPTT range for heparin is 60-85 seconds, corresponding to anti-factor Xa levels of 0.35-0.7 U/mL, as recommended by clinical guidelines 2, 3
aPTT should be measured 6 hours after the initial heparin bolus dose, then adjusted according to established nomograms, with a strength of evidence level of moderate 2, 3

In critically ill surgical patients with hyperinflammatory states, aPTT shows poor correlation with anti-factor Xa levels, and anti-Xa assay is strongly preferred over aPTT for monitoring therapeutic UFH, with a high strength of evidence 4, 5
Elevated factor VIII and fibrinogen levels cause heparin resistance, where aPTT normalizes despite adequate heparin effect, highlighting the need for alternative monitoring strategies 4, 5

Subtherapeutic aPTT (<50 seconds) increases thrombotic risk 15-fold in surgical patients requiring anticoagulation, emphasizing the importance of accurate monitoring 2, 3
Platelet count must be monitored weekly in surgical patients on UFH to detect heparin-induced thrombocytopenia, with a moderate strength of evidence 4, 5

For heparin monitoring, use aPTT in stable surgical patients without inflammation (target 60-85 seconds), and switch to anti-Xa monitoring in critically ill patients with hyperinflammation or heparin resistance (target 0.35-0.7 U/mL) 2, 3, 4, 5
Monitor platelet count on day 5, then every 2-3 days, to minimize the risk of heparin-induced thrombocytopenia, with a low strength of evidence 7